All News
Filter News
Found 7,318 articles
-
Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses
4/27/2020
Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, announced today that it has filed a provisional patent application on the combination of nanoparticle-Actinomycin D (NP-ACT D) with anti-interleukin-6 receptor monoclonal antibody (anti-IL-6R) as a potential therapy for management of COVID-19 disease.
-
Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate
4/27/2020
Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, announced positive immunogenicity data from its preclinical study for the Company’s COVID-19 Vaccine.
-
ROME Therapeutics Launches to Develop Novel Therapies for Cancer and Autoimmune Diseases by Harnessing the Power of the Repeatome
4/27/2020
$50 Million Series A Financing Led by GV and ARCH Venture Partners with Participation from Partners Innovation Fund
-
Intercept to Announce First Quarter 2020 Financial Results on May 11, 2020
4/27/2020
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2020 financial results prior to market open on Monday, May 11, 2020. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results. The conferenc
-
Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia
4/24/2020
Nanoparticle Actinomycin formulation minimizes toxicity and enhances tolerability by slow release of drug to control Cmax in blood This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, United Kingdom, April 24, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, ann
-
TELA Bio Announces Changes to its Board of Directors
4/23/2020
TELA Bio, Inc. announced that it has appointed Doug Evans, the President and Chief Executive Officer of Lungpacer Medical Inc., and Lisa Colleran, a principal of LNC Advisors, LLC, to its board of directors effective April 20, 2020.
-
Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF’s Impact on Breast Cancer
4/23/2020
Neutralization of Soluble TNF may decrease progression of breast cancer and lessen resistance to breast cancer immunotherapy
-
Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020
4/23/2020
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will release financial results for the first quarter 2020, after the market close on Thursday, April 30, 2020.
-
Coherus BioSciences to Report First Quarter Financial Results on May 7th
4/22/2020
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will be released after market close on Thursday, May 7, 2020.
-
INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells
4/22/2020
INmune Bio, Inc. announced that the United States Patent and Trademark Office has given formal notice of allowance in patent application serial no. 15/268,399, titled “IN VIVO PRIMING OF NATURAL KILLER CELLS,”
-
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4/21/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, announced the closing on April 20, 2020 of its previously announced underwritten public offering of 4,735,297 shares of its common stock at a price of $17.00 per share, which included the exercise in full by the underwr
-
Acquist Therapeutics Expands Patent Portfolio for Novel Small Molecules, Receives Fourth U.S. Composition Patent
4/21/2020
Acquist Therapeutics, Inc ., a biopharmaceutical company committed to discovery of new treatments for people with inflammatory diseases, today announced that the Company received a fourth patent from the U.S. Patent Office that cove
-
Poxel Announces First Quarter 2020 Financial and Corporate Update
4/21/2020
POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2020.
-
VALBIOTIS publishes its annual results for 2019
4/21/2020
VALBIOTIS, a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its results for the 2019 fiscal year and reviews its recent milestone achievements.
-
Applied Molecular Transport Appoints Industry Veteran Shawn Cross as Chief Financial Officer and Promotes Bittoo Kanwar, M.D. to Chief Medical Officer
4/21/2020
Applied Molecular Transport, a clinical-stage biopharmaceutical company, announced the appointment of Shawn Cross as the company’s chief financial officer and the promotion of Bittoo Kanwar, M.D. to chief medical officer.
-
MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
4/20/2020
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of glioblastoma.
-
Median Technologies Receives a Disbursement of €15 Million, Corresponding to the First Tranche of the Loan Granted by the European Investment Bank
4/20/2020
Median Technologies (Paris:ALMDT), The Imaging Phenomics Company® announced today that it had received the disbursement of €15 million, corresponding to the first tranche of the loan granted by the European Investment Bank (EIB).
-
Poxel Announces Publication of Imeglimin Clinical Study Results in Clinical Pharmacokinetics
4/20/2020
POXEL SA (Euronext –POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the publication of results from two clinical studies that evaluated the potential for drug-drug interactions of Imeglimin with two widely prescribed medications, metformin or sitagliptin.
-
INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19
4/20/2020
INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced the initiation of a therapeutic program to treat patients with pulmonary complications from COVID-19 infection with its dominant-negative TNF inhibitor (DN-TNF) platform.
-
Poxel Announces Availability of 2019 Universal Registration Document and Provides Business Update
4/20/2020
POXEL SA announced that the Universal Registration Document for the year ended December 31, 2019 has been filed with the stock market regulator in France, Autorité des Marchés Financiers.